Overview
NanoGroup SA is building a biotechnology group and developing projects in nanotechnology for medicine. Its projects include NanOX Recovery Box, NanOX 4 Kidney, AUX-001, and a pipeline with dextran conjugates and aptamers. The company also lists development milestones such as non-GLP studies, GMP batch production, and CE certification.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 2.46
- High
- PLN 2.47
- Low
- PLN 2.41
- Volume
- 9.98K
- Avg. vol.
- 34.67K
- Market cap
- PLN 105.29M
- P/E ratio
- —
- EPS
- -PLN 0.27
- Shares outstanding
- 42.63M
- 52-week
- PLN 2.41 – 2.50
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLNNGRP00011
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD -33.77k | USD -1.19m | USD -1.16m |
| Q1 2026 | USD 33.77k | USD -613.99k | USD -604.27k |
| Q4 2025 | USD -1.76k | USD -972.12k | USD -963.84k |
| Q3 2025 | USD 1.76k | USD -331.74k | USD -284.53k |
Results for Q3 2026:Oct 29, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
News
NanoGroup shareholders decided on share issue at PLN 4.20 related to acquisition of Auxilius Pharma SA
Shareholders holding 35.85% votes reached agreement before NanoGroup EGM. Next step towards Auxilius Pharma joining the Group
Auxilius Pharma takes next step in development of AUX-001 project
NanoGroup starts preparations of NanOX for US market entry. Dedicated team led by Dr. hab. Tomasz Zastawny appointed
NanoGroup convenes EGM on August 26. Next stage of finalizing transaction with Auxilius Pharma
NanoGroup S.A. selects CRO center and starts preclinical research phase of NanOX 4 Kidney in a large animal model.
Industry
Bank accounts
Registered as a VAT taxpayer on 2017-07-20. Active
63 1090 1870 0000 0001 3614 6531- 61 1090 1870 0000 0001 3350 9428
- 61 1090 1870 0000 0001 4121 1228
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 21, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $4 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 23, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282 | Prezydent Miasta Stołecznego Warszawy | |
| Apr 28, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1 | Prezes Zakładu Ubezpieczeń Społecznych |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
The following persons are authorized to make declarations of will on behalf of the company: in the case of a one-person management board, the President of the Management Board; in the case of a multi-member management board, two members of the management board or a member of the management board jointly with a commercial proxy.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Nanogroup.
Subsidiaries
| Name | Share value | Stake | |
|---|---|---|---|
Doto Medicalsp. z o.o. | 21,907.08 USD | 100% |
Capital group
| Name | Ownership |
|---|---|
Startventure@Poland Sp. z o.o  | 6.15% |
Grupa Kapitałowa NanoGroup SA | 7.17% |
| 41% |
Competitors
Selected automatically: mainly by similarity of the business description, plus comparable revenue, industry (PKD code) and location. Only companies with a complete profile (including a logo and financial data) are shown. The list is indicative.
| Name | Revenue | Website | |
|---|---|---|---|
| Embud 2S.K.A. | $47,948,518.33 | embud2ska.pl | |
| Cemat Real EstateS.A. | $5,366,905.27 | cematrealestate.com | |
| BBI DevelopmentS.A. | $3,757,157.21 | bbidevelopment.pl | |
| Duda HoldingS.A. | $3,256,933.00 | dh.pl | |
| 5TH Avenue HoldingS.A. | $456,251.74 | 5avenueholding.com | |
| Amestsp. z o.o. | $403,608.15 | amest.pl | |
| EurofinanceS.A. | $402,748.34 | eurofinancesa.pl | |
| Invest-Motsp. z o.o. | $71,515.18 | invest-mot.com.pl | |
| ABRE Holdingsp. z o.o. | $28,477.19 | abredevelopment.pl | |
| EQUOS.A. | $10,394.96 | equo.pl |
Change history
| Date | Event |
|---|---|
| 2026-03-31 | Share capital change (32,813,238.00 PLN → 42,628,988.00 PLN) |
| 2025-10-14 | Share capital change (32,164,563.00 PLN → 32,813,238.00 PLN) |
| 2025-04-09 | Share capital change (32,158,853.00 PLN → 32,164,563.00 PLN) |
| 2024-12-10 | Share capital change (28,654,093.00 PLN → 32,158,853.00 PLN) |
| 2024-10-10 | Share capital change (25,558,854.00 PLN → 28,654,093.00 PLN) |
FAQ
Last updated: 2026-07-17